| Authors: |
Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org khazaie@mayo.edu gounderm@mskcc.org., Zhang HH; BioMed Valley Discoveries Inc., Kansas City, Missouri., Pezeshki A; Department of Immunology, Mayo Clinic, Rochester, Minnesota., Goel S; Montefiore/Albert Einstein Cancer Center, Bronx, New York., Murthy R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang-Gillam A; Washington University in St. Louis, St. Louis, Missouri., Shepard DR; Cleveland Clinic, Cleveland, Ohio., Helgason T; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Masters T; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Klang M; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Huang SY; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sakamuri D; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Raina A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Torrisi J; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Solomon SB; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Weissfeld A; Microbiology Specialists Inc., Houston, Texas., Trevino E; Microbiology Specialists Inc., Houston, Texas., DeCrescenzo G; BioMed Valley Discoveries Inc., Kansas City, Missouri., Collins A; BioMed Valley Discoveries Inc., Kansas City, Missouri., Miller M; BioMed Valley Discoveries Inc., Kansas City, Missouri., Salstrom JL; PAREXEL International, Waltham, Massachusetts., Korn RL; Imaging Endpoints, Scottsdale, Arizona., Zhang L; BioMed Valley Discoveries Inc., Kansas City, Missouri., Saha S; BioMed Valley Discoveries Inc., Kansas City, Missouri.; Atlas Venture, Boston, Massachusetts., Leontovich AA; Biomedical Informatics, Mayo Clinic, Rochester, Minnesota., Tung D; BioMed Valley Discoveries Inc., Kansas City, Missouri., Kreider B; BioMed Valley Discoveries Inc., Kansas City, Missouri., Varterasian M; BioMed Valley Discoveries Inc., Kansas City, Missouri., Khazaie K; Department of Immunology, Mayo Clinic, Rochester, Minnesota. fjanku@mdanderson.org khazaie@mayo.edu gounderm@mskcc.org., Gounder MM; Early Drug Development Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York. fjanku@mdanderson.org khazaie@mayo.edu gounderm@mskcc.org. |
